POLA KLINIS KANKER PARU DI RSUP DR. KARIADI SEMARANG PERIODE JULI 2013- JULI 2014 - Diponegoro University | Institutional Repository (UNDIP-IR) BAB VIIIHASIL KTI
DAFTAR PUSTAKA
1.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non small cell lung
cancer: Epidemiology, risk factors, treatment, and survioship. Mayo Clin Proc
2008; 83: 584-94
2.
Rasyid R, Kamso S, Suratman E, Bestral. The characteristics and two-year
survival rate of lung cancer patients at Dharmais Cancer Hospital in period
January
1998-November
2001.available
from:
http://www.ekologi.litbang.depkes.go.id/
3.
Aditiawarman. Hubungan ketahanan hidup 1 tahun penderita kanker paru
yang dirawat di RS Dr. Kariadi Semarang dengan faktor-faktor yang
berhubungan. Karya akhir PPDS I. FK UNDIP, 2003.available from:
http://www.eprints.undip.ac.id
4.
World Health Organization. Passive Smoking Does Cause Lung Cancer.
WHO:1998.
5.
Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist
referral time. Eur Respir J 2004; 24: 898–904
6.
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging
Project: proposals for the revision of the TNM stage groupings in the
forthcoming (seventh) edition of the TNM Classification of malignant
tumours. Journal of thoracic oncology : official publication of the
International Association for the Study of Lung Cancer 2007;2:706-14
7.
National Comprehensive Cancer Network Guidelines V 2.2013. Available
from: http://www.nccn.org.. Accessed May 11, 2013
8.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer
statistics. CA: a cancer journal for clinicians 2011; 61 (2): 69–90
9.
American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American
Cancer Society; 2012.
10. Lam PT, Leung MW, Tse CY. Identifying prognostic factors for survival in
advanced cancer patients: A prospective study. Hong Kong: Med J ;2007;
13: 453-9
11. Josen K, Siegel R, Kamp D. Incidence and Epidemiology. In Weitberg AB.
Cancer of the Lung From Melecular Biology to Treatment Guidelines. New
Jersey. Humana Press; 2002 :3-26
12. Deaen W.Tumor Paru Di Daerah Toraks. In : Tiehua R, Yixin Z, Zongyuan Z,
Jingqing L, Yilong W, Zhuming G. Buku Ajar Ankologi Klinis. Jakarta. Balai
Penerbit FK UI; 2008: 337-50
58
59
13. Senby C. Neoplastic Disease. In : Respiratory Medicine. New York.Churchill
Livingstone; 2002 : 54-9
14. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF,
Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS,
Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011,
National Cancer Institute.
15. Haugen A, Mollerup S. Etiology of Lung Cancer. In : Hansen H. Lung Cancer.
London. Informa Healthcare;2000: 1-8
16. Prokhorov AV, Ford KH, Hudmon KS. Smoking Cassation. In : Roth JA,
Hong WK, Cox JD. Lung Cancer. USA. Blackwell Publishing;2008: 1-20
17. Boyle P, Gandini S, Gray N. Epidemiology of Lung Cancer: A Century of
Great Success and Ignominious Failure. In : Hansen H. Textbook of Lung
cancer. USA. Informa Healthcare; 2008:10-18
18. Ward JPT, Ward J, Leach RM, Wiener C. Kanker Paru In : At a Glance Sistem
Respirasi. Jakarta. Arlangga;2007:84
19. Minaa JD: Neoplasma of The Lung.in Ed Principles of Internal
Medicine.16th.McGraw-Hill Med Pub Div.2005.p 506-516
20. Jablonski A, Gift AG, Stommel M, Given CW. Symptom clusters in elderly
patients with lung cancer. 2004 ;31(2), 203-212
21. Horn L, Pao W, Johnson DH (2012). "Chapter 89". In Longo, DL; Kasper,
DL; Jameson, JL; Fauci, AS; Hauser, SL; Loscalzo, J. Harrison's Principles of
Internal Medicine (ed. 18th). McGraw-Hill
22. Honnorat J, Antoine JC (May 2007). Paraneoplastic neurological
syndromes"Orphanet Journal of Rare Diseases (BioMed Central) 2 (1): 22
23. Minna JD. Neoplasma of the lung. In Fauci AS, Braunwald E, Kasper DL,
Hauser SL, et al. (editors) Harrison’s principles of internal medicine. 17th ed.
New York. McGraw Hill. 2009:506
24. Brasher VL. Kanker paru. Dalam Devi Y. Aplikasi klinis patofisiologi,
pemeriksaan dan manajemen. Cetakan I. Jakarta: Penerbit Buku Kedokteran
EGC,2008
25. York E, Miller. Pathogenesis of Lung Cancer: Centennial Review. Am J
Respir Mol Biol. 2005; 33.p216-223
26. Perhimpunan Dokter Paru
Penatalaksanaan di Indonesia
Indonesia(2003).Pedoman
Diagnosis
dan
27. Giaccone G. The potensial of antiangiogenic therapy in non-small cell lung
cancer. Clin Can Resp 2007
60
28. Timbrel R.Lung Cancer : A review of current treatment modalities with a on
new strategies. Eradimaging: 2009
29. Jusuf A, Mariono SA, Tambunan KL, Reksodiputro AA, Soetantio N,
Hukom R, et al : Experience of treatment of lung cancer patients using
paclitaxel and carboplatin. Med. J. Ind. 2000;9:43-8
30. Jeong HC, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, et al. Phase II study of
irinotecan plus cisplatin with concurrent radiotherapy for the patients with
limited-disease small-cell lung cancer. Lung Cancer 2006 Sep;53(3):361-6
31. Jusuf A, Harryanto A, Syahruddin E, Endardjo S, Mudjiantoro S, Sutantio N.
Kanker paru jenis karsinoma bukan sel kecil. Pedoman Nasional untuk
diagnosis dan penatalaksanaan di Indonesia 2005. Ed. Jusuf A,Syahruddin E.
PDPI dan POI, Jakarta 2005
32. Supartono, Agus S. Faktor yang mempengaruhi ketahanan hidup penderita
kanker paru di RSUP Dr. Kariadi Semarang. Med Hos. 2012; vol 1(1):25-31
33. Penninx BW, Cohen HJ, Woodman C. Anemia and cancer in older person. J
Support Oncol 2007;5:107-113.
34. Sugiura S, Ando Y, Minami H, et all. Prognostic Value of pleural effusion in
patients with non small cell lung cancer. Clinical Cancer Research
1997;3:47-50
35. Forest LM, McMillian, McArdle. A prospective longitudinal study of
performance status, an inflamation based score and survival in patient with
inoperable non small cell lung cancer. British Journal of Cancer 2005; 92,
1834-1836
36. Williamson JP, Phillips MJ, Hillman DR, Eastwood PR. Managing
obstruction of the central airways.Intern Med J. 2010;40(6):399–410)
37. Nichols L, Saunders R, Friedrich. Cause of death of patient with lung cancer.
Arch Pathol Lab Med. 2012;136:1552–1557
38. Metha A, Masrul B, Henny M. Hubungan karakteristik penderita dengan
gambaran sitopatologi pada kasus karsinoma paru yang dirawat di RSUP Dr.
M. Djamil Padang. J kes and. 2014;3(2)
39. Aziza I, Faisal, Elisna, Pudjo A, Heriawaty H, Juedo P. Kriteria diagnosis
kanker paru berdasarkan gambaran morfologi pada ct-scan toraks. J kanker
indo.2008; 1,3-8
40. Amira A, Elisna S, Wahju A, Indah S, Agus D. Analisis penyebab kematian
pasien kanker paru. J respi indo.2014; 34:11-6
Lampiran 1
61
Lampiran 2
62
Lampiran 3
63
Biodata Mahasiswa
Identitas
Nama
: Ardina Filindri Purba
NIM
: 22010111120044
Tempat tanggal lahir
: Binjai, 07 Februari 1994
Jenis Kelamin
: Perempuan
Alamat
: Jl. Taut gg Marjan NO 6, Medan
No. Hp
: 082272816102
Email
: ardinapurba@yahoo.com
Riwayat Pendidikan Formal
:
1. SD : SDN 060786 MEDAN
2. SMP : SMP N 12 MEDAN
3. SMA : SMA N 1 MEDAN
4. SI
: Fakultas Kedokteran Universitas Diponegoro
1.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non small cell lung
cancer: Epidemiology, risk factors, treatment, and survioship. Mayo Clin Proc
2008; 83: 584-94
2.
Rasyid R, Kamso S, Suratman E, Bestral. The characteristics and two-year
survival rate of lung cancer patients at Dharmais Cancer Hospital in period
January
1998-November
2001.available
from:
http://www.ekologi.litbang.depkes.go.id/
3.
Aditiawarman. Hubungan ketahanan hidup 1 tahun penderita kanker paru
yang dirawat di RS Dr. Kariadi Semarang dengan faktor-faktor yang
berhubungan. Karya akhir PPDS I. FK UNDIP, 2003.available from:
http://www.eprints.undip.ac.id
4.
World Health Organization. Passive Smoking Does Cause Lung Cancer.
WHO:1998.
5.
Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist
referral time. Eur Respir J 2004; 24: 898–904
6.
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging
Project: proposals for the revision of the TNM stage groupings in the
forthcoming (seventh) edition of the TNM Classification of malignant
tumours. Journal of thoracic oncology : official publication of the
International Association for the Study of Lung Cancer 2007;2:706-14
7.
National Comprehensive Cancer Network Guidelines V 2.2013. Available
from: http://www.nccn.org.. Accessed May 11, 2013
8.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.Global cancer
statistics. CA: a cancer journal for clinicians 2011; 61 (2): 69–90
9.
American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American
Cancer Society; 2012.
10. Lam PT, Leung MW, Tse CY. Identifying prognostic factors for survival in
advanced cancer patients: A prospective study. Hong Kong: Med J ;2007;
13: 453-9
11. Josen K, Siegel R, Kamp D. Incidence and Epidemiology. In Weitberg AB.
Cancer of the Lung From Melecular Biology to Treatment Guidelines. New
Jersey. Humana Press; 2002 :3-26
12. Deaen W.Tumor Paru Di Daerah Toraks. In : Tiehua R, Yixin Z, Zongyuan Z,
Jingqing L, Yilong W, Zhuming G. Buku Ajar Ankologi Klinis. Jakarta. Balai
Penerbit FK UI; 2008: 337-50
58
59
13. Senby C. Neoplastic Disease. In : Respiratory Medicine. New York.Churchill
Livingstone; 2002 : 54-9
14. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF,
Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS,
Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011,
National Cancer Institute.
15. Haugen A, Mollerup S. Etiology of Lung Cancer. In : Hansen H. Lung Cancer.
London. Informa Healthcare;2000: 1-8
16. Prokhorov AV, Ford KH, Hudmon KS. Smoking Cassation. In : Roth JA,
Hong WK, Cox JD. Lung Cancer. USA. Blackwell Publishing;2008: 1-20
17. Boyle P, Gandini S, Gray N. Epidemiology of Lung Cancer: A Century of
Great Success and Ignominious Failure. In : Hansen H. Textbook of Lung
cancer. USA. Informa Healthcare; 2008:10-18
18. Ward JPT, Ward J, Leach RM, Wiener C. Kanker Paru In : At a Glance Sistem
Respirasi. Jakarta. Arlangga;2007:84
19. Minaa JD: Neoplasma of The Lung.in Ed Principles of Internal
Medicine.16th.McGraw-Hill Med Pub Div.2005.p 506-516
20. Jablonski A, Gift AG, Stommel M, Given CW. Symptom clusters in elderly
patients with lung cancer. 2004 ;31(2), 203-212
21. Horn L, Pao W, Johnson DH (2012). "Chapter 89". In Longo, DL; Kasper,
DL; Jameson, JL; Fauci, AS; Hauser, SL; Loscalzo, J. Harrison's Principles of
Internal Medicine (ed. 18th). McGraw-Hill
22. Honnorat J, Antoine JC (May 2007). Paraneoplastic neurological
syndromes"Orphanet Journal of Rare Diseases (BioMed Central) 2 (1): 22
23. Minna JD. Neoplasma of the lung. In Fauci AS, Braunwald E, Kasper DL,
Hauser SL, et al. (editors) Harrison’s principles of internal medicine. 17th ed.
New York. McGraw Hill. 2009:506
24. Brasher VL. Kanker paru. Dalam Devi Y. Aplikasi klinis patofisiologi,
pemeriksaan dan manajemen. Cetakan I. Jakarta: Penerbit Buku Kedokteran
EGC,2008
25. York E, Miller. Pathogenesis of Lung Cancer: Centennial Review. Am J
Respir Mol Biol. 2005; 33.p216-223
26. Perhimpunan Dokter Paru
Penatalaksanaan di Indonesia
Indonesia(2003).Pedoman
Diagnosis
dan
27. Giaccone G. The potensial of antiangiogenic therapy in non-small cell lung
cancer. Clin Can Resp 2007
60
28. Timbrel R.Lung Cancer : A review of current treatment modalities with a on
new strategies. Eradimaging: 2009
29. Jusuf A, Mariono SA, Tambunan KL, Reksodiputro AA, Soetantio N,
Hukom R, et al : Experience of treatment of lung cancer patients using
paclitaxel and carboplatin. Med. J. Ind. 2000;9:43-8
30. Jeong HC, Lee SY, Lee SY, Kim JH, Shin C, Shim JJ, et al. Phase II study of
irinotecan plus cisplatin with concurrent radiotherapy for the patients with
limited-disease small-cell lung cancer. Lung Cancer 2006 Sep;53(3):361-6
31. Jusuf A, Harryanto A, Syahruddin E, Endardjo S, Mudjiantoro S, Sutantio N.
Kanker paru jenis karsinoma bukan sel kecil. Pedoman Nasional untuk
diagnosis dan penatalaksanaan di Indonesia 2005. Ed. Jusuf A,Syahruddin E.
PDPI dan POI, Jakarta 2005
32. Supartono, Agus S. Faktor yang mempengaruhi ketahanan hidup penderita
kanker paru di RSUP Dr. Kariadi Semarang. Med Hos. 2012; vol 1(1):25-31
33. Penninx BW, Cohen HJ, Woodman C. Anemia and cancer in older person. J
Support Oncol 2007;5:107-113.
34. Sugiura S, Ando Y, Minami H, et all. Prognostic Value of pleural effusion in
patients with non small cell lung cancer. Clinical Cancer Research
1997;3:47-50
35. Forest LM, McMillian, McArdle. A prospective longitudinal study of
performance status, an inflamation based score and survival in patient with
inoperable non small cell lung cancer. British Journal of Cancer 2005; 92,
1834-1836
36. Williamson JP, Phillips MJ, Hillman DR, Eastwood PR. Managing
obstruction of the central airways.Intern Med J. 2010;40(6):399–410)
37. Nichols L, Saunders R, Friedrich. Cause of death of patient with lung cancer.
Arch Pathol Lab Med. 2012;136:1552–1557
38. Metha A, Masrul B, Henny M. Hubungan karakteristik penderita dengan
gambaran sitopatologi pada kasus karsinoma paru yang dirawat di RSUP Dr.
M. Djamil Padang. J kes and. 2014;3(2)
39. Aziza I, Faisal, Elisna, Pudjo A, Heriawaty H, Juedo P. Kriteria diagnosis
kanker paru berdasarkan gambaran morfologi pada ct-scan toraks. J kanker
indo.2008; 1,3-8
40. Amira A, Elisna S, Wahju A, Indah S, Agus D. Analisis penyebab kematian
pasien kanker paru. J respi indo.2014; 34:11-6
Lampiran 1
61
Lampiran 2
62
Lampiran 3
63
Biodata Mahasiswa
Identitas
Nama
: Ardina Filindri Purba
NIM
: 22010111120044
Tempat tanggal lahir
: Binjai, 07 Februari 1994
Jenis Kelamin
: Perempuan
Alamat
: Jl. Taut gg Marjan NO 6, Medan
No. Hp
: 082272816102
: ardinapurba@yahoo.com
Riwayat Pendidikan Formal
:
1. SD : SDN 060786 MEDAN
2. SMP : SMP N 12 MEDAN
3. SMA : SMA N 1 MEDAN
4. SI
: Fakultas Kedokteran Universitas Diponegoro